Introduction {#Sec1}
============

Lyme disease or Lyme borreliosis (LB) is caused in humans by at least three genospecies of the *Borrelia burgdorferi* sensu lato complex: *B. burgdorferi*, *B. garinii* and *B. afzelii*. A bite from an infected *Ixodes scapularis* and *Ixodes pacificus* blacklegged ticks initiates this bacterial infection that leads to LB. The early stage of the disease can develop later to a number of long-term complications such as Lyme arthritis (LA) and Lyme carditis \[[@CR1]\]. In North America and Europe, LB presently is the most common vector-borne disease \[[@CR1]\] with \> 30,000 cases reported annually in the USA \[[@CR2]\]. However, the actual prevalence estimates are thought to be up to ten times as high because of the underreporting \[[@CR3]\]. Moreover, approximately sixfold increased incidence in LB was noted in Canada between 2009 (128 cases) and 2015 (707 cases) \[[@CR4]\].

Early symptoms of LB usually start 1--2 weeks following the tick bite with a proportion of the infected subjects developing the characteristic erythema migrans (EM) rash. EM can last for a period of 4 weeks or more. Symptoms such as headache, myalgia, fever, malaise, fatigue and chills may also accompany this stage. If untreated, systemic dissemination of the bacteria may occur via the lymphatic system or blood to the cardiovascular system, nervous system and joints. Weeks to months after the tick bite, early disseminated LB may emerge with symptoms such as Lyme-associated facial nerve palsy and an array of cardiac conditions such as palpitations, shortness of breath or chest pain \[[@CR5]\]. A range of inflammatory processes may occur about 6 months after infection as suggested by the development of joint pain and swelling and synovial fluid findings. Months to years after the initial tick bite, the disease can progress to the late disseminated stage. This stage may lead to substantial morbidity, primarily from persistent arthritis (LA) that may occur in \~ 60% of untreated patients \[[@CR5]\], rendering it as one of the most common long-term consequences of the late disseminated LB stage. In this case, LA clinically manifests as intermittent or persistent arthritis in the joints for several years.

Current recommendations for treatment of LA patients include initial oral doxycycline (100 mg twice daily) or amoxicillin (500 mg thrice daily) for 30 days. In patients who are unable to take either of these agents, cefuroxime axetil (500 mg twice daily) may be used as an alternative \[[@CR6]\]. In patients with antibiotic-refractory LA (A-RLA) treated with antibiotics, PCR testing for *B. burgdorferi* DNA in the affected joint fluid is usually negative, which suggests that the A-RLA persists despite near or total eradication of the pathogen from the joint \[[@CR7]\]. One of the major clinical and public health challenges related to A-RLA is the lack of ability to determine which LB patients may develop A-RLA \[[@CR8]\]. This is particularly true given the possible post-treatment eradication of the pathogen \[[@CR9]\]. Biologic markers evaluated prior to or at the time of treatment may be useful in the prediction of those individuals who may be at risk of developing A-RLA \[[@CR9]\].

We conducted a systematic review to summarize the literature documenting the changes in immunologic (e.g., immune response or cytokine and chemokine expression) and genetic biomarkers (e.g., expression and polymorphisms in genes regulating the immune system) in response to LB and their role in the development of A-RLA. The objective of this study was to evaluate the potential predictive value of these biomarkers in the progression of LA to A-RLA.

Methods {#Sec2}
=======

Literature Search {#Sec3}
-----------------

We conducted a systematic review of studies examining biomarkers among patients with A-RLA from MEDLINE via OVID, EMBASE and Web of Science. We examined studies published from 1 January 1982 to 15 December 2017. A broad search using the following MeSH terms was conducted: (Lyme) AND (arthritis) AND (antibiotic-refractory OR antibiotic OR refractory). We limited our search to studies conducted in humans and published in English with the inclusion of biologic markers associated with or predictive of disease risk and/or prognosis. The systematic review was conducted in line with the Preferred Reporting for Systematic Review and Meta-Analyses (PRISMA; see Fig. [1](#Fig1){ref-type="fig"} and Supplementary Table 1) \[[@CR10]\]. All abstracts and titles were screened independently in duplicate with any conflicts determined by a third reviewer.Fig. 1Flowchart of the study selection and systematic literature review process. The flow diagram describes the systematic review of literature on the biologic markers of antibiotic-refractory LA in humans. A total of 26 unique studies were identified for qualitative analysis

Inclusion and Exclusion Criteria {#Sec4}
--------------------------------

Inclusion and exclusion criteria were defined using the Population, Exposure, Comparator, Outcome, Study Design (PECOS) table (Supplementary Table 2). We included studies examining biologic markers of any type among adults or children with no age or sex restrictions. The exposure of interest was LA. A broad array of outcomes of interest was included, such as associations of biomarkers with A-RLA in a population sample, association of biomarkers with A-RLA compared with responsive LA and prediction of A-RLA at the time of diagnosis of LA. Any potentially relevant study design, either intervention or observational, was included. Case reports and review articles were excluded. Studies prior to 1982 were not considered as it is the discovery date of *B. burgdorferi*. Only publications in English were included in this study.

Data Extraction {#Sec5}
---------------

We developed and tested a data extraction template using two blinded reviewers. All relevant study and population characteristics were extracted in addition to specific methods around biologic sample collection and biomarker quantification (Supplementary Table 3). All data extracted were performed in duplicate. Upon completion of data extraction, we grouped studies into those reporting associations with immune response and genetic biomarkers separately for synthesis and comparative discussion.

Compliance with Ethics Guidelines {#Sec6}
---------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec7}
=======

In total, 26 studies were identified that met the specified search criteria and contained relevant results of interest, which are summarized in Table [1](#Tab1){ref-type="table"}. All studies were of patient populations from the USA, with the exception of one from Germany \[[@CR11]\]. These studies represented a relatively homogeneous study population, with most cases being ascertained from Tufts Medical Center or Massachusetts General Hospital \[[@CR12]--[@CR26]\]. However, there were a few reports that did not state where cases were ascertained \[[@CR17]\], many of which were conference abstracts \[[@CR28]--[@CR35]\]. One study was conducted across the USA \[[@CR36]\]. Of the studies that reported sex distributions within the study populations, all included both males and females \[[@CR11], [@CR12], [@CR17], [@CR18], [@CR20]--[@CR25], [@CR36]\]. In addition, of the studies that reported study population ages, most were from adult populations but also included children above the age of 12 years \[[@CR17], [@CR18], [@CR20]--[@CR25]\]. The study from Germany \[[@CR11]\] was exclusively from a pediatric population with two reports that were only in adults \[[@CR12], [@CR36]\]. All biologic samples used for analysis were derived from peripheral blood, serum or synovial fluid and/or tissue.Table 1Characteristics of the selected studiesObjectiveStudy^a^Number of subjectsMales (%)Age (years)SpecimensA-RLAComparative group(s)RangeAverageEtiology of A-RLA vs. responsive LA and/or other arthritisStrle et al. 2017 \[[@CR13]\]8160 Antibiotic-responsive LASerum and SFCrowley et al. 2016 \[[@CR14]\]11458 Healthy controls\
91 Antibiotic-responsive LASerum, PBMCs, SFStrle et al. 2014 \[[@CR31]\]159SFDrouin et al. 2013 \[[@CR19]\]10974 Healthy controls\
21 Rheumatoid arthritis\
77 Antibiotic-responsive LASF and serumStrle et al. 2012 \[[@CR21]\]10176 Antibiotic-responsive LA12--79PBMCsStrle et al. 2011 \[[@CR35]\]125 Antibiotic-responsive LASFKannian et al. 2007 \[[@CR24]\]4123 Antibiotic-responsive LA6613--6441SerumShin et al. 2007 \[[@CR25]\]3517 Antibiotic-responsive LA7512--7938SF and tissueNimmrich et al. 2014 \[[@CR11]\]\*823 Antibiotic-responsive LA37.511 ± 2SerumLondono et al. 2014 \[[@CR17]\]146 Other arthritis5011--4316SFVudattu et al. 2011 \[[@CR34]\]1615 Antibiotic-responsive LAPBMCs and SF mononuclear cellsShen et al. 2010 \[[@CR22]\]126 Antibiotic-responsive LA6711--5429PBMCs and SF mononuclear cellsKannian et al. 2007 \[[@CR23]\]76 Antibiotic-responsive LA7712--6425PBMCs and SF mononuclear cellsLochhead et al. 2017 \[[@CR12]\]275 Pre-treatment controls\
8 Other arthritis6917--7645SFLochhead et al. 2015 \[[@CR29]\]106 Antibiotic-responsive LA\
5 Other arthritisSFStrle et al. 2011 \[[@CR27]\]10176 Antibiotic-responsive LASFSteere et al. 2006 \[[@CR26]\]7150 Antibiotic-responsive LANot specifiedMechanisms of A-RLA vs. healthy controlsPianta et al. 2015 \[[@CR15]\]8952 Healthy controlsSerum, SFCrowley et al. 2015 \[[@CR16]\]9457 Healthy controlsSerum, SFVudattu et al. 2013 \[[@CR18]\]1615 Antibiotic-responsive LA 13 healthy controls6912--6229Peripheral blood and SFCrowley et al. 2015 \[[@CR30]\]114SFCrowley et al. 2014 \[[@CR32]\]SerumPianta et al. 2014 \[[@CR33]\]SF and serumKatchar et al. 2013 \[[@CR20]\]158 Antibiotic-responsive LA\
4 Healthy controls5312--7829Peripheral blood and SFGenetics of A-RLAStrle et al. 2015 \[[@CR28]\]SFEarly vs. late manifestations of LDUhde et al. 2016 \[[@CR36]\]1167 Healthy controls63.653 ± 21SerumAll studies were of patient populations from the USA, except as noted (\*) from Germany*A-RLA* antibiotic-refractory Lyme arthritis, *EM* erythema migrans, *RA* rheumatoid arthritis, *PBMCs* peripheral blood mononuclear cells, *FS* synovial fluid, *LD* Lyme disease^a^Empty cells denote information not available from the original study

The immune responses to *B. burgdorferi*, its antigens, or other proteins in A-RLA were evaluated in ten studies \[[@CR14]--[@CR16], [@CR19], [@CR24], [@CR28], [@CR30]--[@CR33]\], whereas six studies examined other biomarkers (predominantly immune markers) of A-RLA \[[@CR11], [@CR13], [@CR17], [@CR21], [@CR27], [@CR36]\]. Of the selected studies, five examined various types of immune cells in A-RLA \[[@CR18], [@CR20], [@CR22], [@CR23], [@CR34]\], while five other studies evaluated an array of genetic markers \[[@CR12], [@CR26], [@CR28], [@CR29], [@CR35]\]. As shown in Table [2](#Tab2){ref-type="table"}, the studies that investigated immune responses demonstrated significantly higher reactivity to matrix metalloproteinase (MMP)-10 \[[@CR14], [@CR30]\], annexin A2 \[[@CR15], [@CR33]\], apolipoprotein B-100 \[[@CR16], [@CR32]\] and endothelial cell growth factor (ECGF) \[[@CR19]\] in A-RLA patients compared with healthy controls. Additionally, compared with antibiotic-responsive LA, A-RLA patients had significantly higher reactivity to the variable major protein-like sequence-expressed (VlsE) lipoprotein \[[@CR24]\] as well as to human ECGF (hECGF) \[[@CR31]\]. When stimulated with *B. burgdorferi* or interferon (IFN)-γ, A-RLA patients also exhibited particularly high levels of MMP-1, MMP-2, MMP-3, MMP-9, MMP-13, interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor (TNF), C--C motif chemokine ligand (CCL)-2, C--X--C motif chemokine ligand (CXCL)-9 and CXCL-10 in fibroblast-like synoviocytes \[[@CR28]\].Table 2Summary of studies reporting immune biomarkers in antibiotic-refractory LA in humansStudyBiomarker classBiomarker(s)AssaySummary of resultsStrle et al. 2017 \[[@CR13]\]Innate immune cytokine responseCCL3, TNF-α, CXCL9, IL-17FLuminex assayA total of 21 mediators associated with innate, T-helper 1 cell and T-helper 17 cell immune responses were assessed in serum and SF\
IL-17F in serum and CCL2, CCL3, TNF-α and CXCL9 in SF were significantly higher in A-RLA compared with antibiotic-responsive LACrowley et al. 2016 \[[@CR14]\]Immune response in A-RLAMMP-10 stimulated PBMCs, serum MMP-10, synovial fluid MMP-10, synovial fluid MMP-3Bead-based multiplex coupled with Luminex assayThe response was specific to MMP-10-stimulated PBMCs that had a significantly higher T-cell and B-cell reactivity in A-RLA compared with healthy controls and antibiotic-responsive LAPianta et al. 2015 \[[@CR15]\]Cytokine response and expressionT-cell reactivity (IFN-γ response) and IgG response to annexin A2/annexin A2 protein levels in SF and serumELISASignificantly higher response (IFN-γ and IgG) to annexin A2 and elevated annexin A2 protein levels (in SF and serum) among A-RLA compared with healthy controlsCrowley et al. 2015 \[[@CR16]\]Cytokine responseT-cell reactivity (IFN-γ response) and IgG response to apolipoprotein B-100 and apolipoprotein B-100 in serumELISAApolipoprotein B-100 protein levels were also significantly higher in serum of A-RLA compared with healthy controls\
Significantly higher IgG response to apolipoprotein B-100 among A-RLA compared with healthy controls\
T-cell reactivity (IFN-γ) was borderline significant (*p* = 0.06) in A-RLA compared with healthy controlsStrle et al. 2015 \[[@CR28]\]Cytokine responseMMP1, MMP2, MMP3, MMP9, MMP13, IL-6, IL-8, IL-10, TNF, CCL2, CXCL9, CXCL10 from FLS simulated with *B. burgdorferi*Luminex assayA total of 8 MMPs and 21 cytokines and chemokines were assayed in FLS\
A-RLA exhibited significantly higher levels of IL-6, IL-8, IL-10, TNFα, CCL2, CXCL9, CXCL10Crowley et al. 2014 \[[@CR32]\]Cytokine responseResponse of T cell (autoantibody) to MMP-10Not specifiedHigher numbers of A-RLA patients had robust or autoantibody T-cell responses to MMP-10---compared with antibiotic-responsive LA, healthy controls or rheumatoid arthritis patientsStrle et al. 2014 \[[@CR31]\]Levels of inflammatory cytokines and chemokines and response to cytokinesTh17-associated mediators and frequency of autoantibody responses to hECGFLuminexHigher levels of Th17 associated mediators (e.g., IL-23) and a greater frequency of autoantibody responses to hECGF among A-RLA compared with antibiotic-responsive LACrowley et al. 2014 \[[@CR32]\]Cytokine responseT-cell and B-cell reactivity (IgG anti-ApoB antibodies) to apolipoprotein B-100ELISASignificantly higher frequency of A-RLA had T-cell and B-cell responses to anti-ApoB IgG antibodies compared with healthy controls and patients with EMPianta et al. 2014 \[[@CR33]\]Cytokine responseAnti-annexin A2 IgG autoantibody response in serumELISASignificantly higher autoantibody response in A-RLA compared with healthy controls, but similar to that in antibiotic-responsive LADrouin et al. 2013 \[[@CR19]\]Autoantibody and autoantigen responsesAnti-ECGF IgG autoantibody response in serum and ECGF in serumELISASignificantly higher number of A-RLA had positive autoantibody responses to ECGF compared with healthy controls\
A-RLA exhibited ECGF autoantibodies more frequently than in antibiotic-responsive LA\
A-RLA showed significantly higher levels of ECGF in SF compared with antibiotic-responsive LAStrle et al. 2012 \[[@CR21]\]\
Strle et al. 2011 \[[@CR35]\]Chemokine and cytokine levelsCXCL9, CXCL10, IL-6, IL-8, IL-10, IL-1β, CCL2, CCL3, CCL4, TNF, IFNγBead-based multiplex assayCXCL9, CXCL10, IL-6, IL-8, IL-10, IL-1β, CCL2, CCL3, CCL4, TNF, IFNγ were more common in (and in significantly higher levels in the SF of) A-RLA compared with antibiotic-responsive LAKannian et al. 2007 \[[@CR23]\]Antibody responseIgG antibody titers in response to *B. burgdorferi* antigens in serumELISAIn A-RLA, during the first 1--3 months after treatment, antibody response to the VlsE peptide declined while the titers to *B. burgdorferi* DbpA, OspA and Arp increased\
Synovial inflammation persisted in A-RLA after infection compared with antibiotic-responsive LAShin et al. 2007 \[[@CR25]\]Chemokines and cytokines levels in response to antibiotic treatmentCXCL8, CXCL9, CXCL10, IL-1β, IL-5, IL-6, CCL2, CCL3, CCL4, TNF, IFNγCytometric bead arrayCompared with antibiotic-responsive LA, A-RLA exhibited significantly higher CXCL8, CXCL9, CXCL10, CCL4, IL-6, IL-1β, TNF and IFNγ during the antibiotic treatment period and higher CXCL9, CXCL10, IL-5, IL-1β, CCL2, CCL3 and CCL4 following the treatmentUhde et al. 2016 \[[@CR36]\]Acute phase reactantsCRP and amyloid AELISASignificantly higher CRP but not amyloid A in A-RLA compared with healthy controlsNimmrich et al. 2014 \[[@CR11]\]Protein expressionp58, OspC, P100, VlsE, P39, Ospa and p18Western blotSignificantly higher IgG p58 and OspC expression---but not P100, VlsE, P39, Ospa and p18---in A-RLA compared with antibiotic-responsive LAVudattu et al. 2013 \[[@CR18]\]LeukocytesMonocytes, CD4^+^ T cells, in peripheral blood or SFFlow cytometryCompared with healthy controls, A-RLA exhibited higher levels of monocytes and CD4^+^ T cells in peripheral blood\
Compared with antibiotic-responsive LA, A-RLA had lower CD4^+^ T cells in SFKatchar et al. 2013 \[[@CR20]\]LymphocytesCD3^+^ T cells in peripheral blood, CD56 bright NK cells and Vα24^+^ iNKT cells in SFFlow cytometryA-RLA had lower CD3^+^ T cells in peripheral blood compared with healthy controls and lower CD56 bright NK cells and Vα24^+^ iNKT cells in SF compared with antibiotic-responsive LAVudattu et al. 2011 \[[@CR34]\]Lymphocytes and phenotypes of lymphocytesCD4^+^ T cells and expression of GITR and OX40 receptorsFlow cytometryIncreased CD4^+^ T cells and GITR and OX40 receptors expression in A-RLA compared with antibiotic-responsive LAShen et al. 2010 \[[@CR22]\]Phenotypes of lymphocytesIL-4^+^CD4^+^Th2 cells, IL-17^+^CD4^+^ T cells, FoxP3^+^Treg cellsFlow cytometrySignificantly higher numbers of IL-4^+^CD4^+^Th2 cells, IL-17^+^CD4^+^T cells and FoxP3^+^Treg cells were found in A-RLA compared with antibiotic-responsive LAKannian et al. 2007 \[[@CR23]\]LymphocytesOspA161--175-specific T cellsFlow cytometryNo significant differences in OspA161--175-specific T-cell frequencies or proliferation responses between A-RLA and antibiotic-responsive LALondono et al. 2014 \[[@CR17]\]Histologic findingsLining layer thickness, global cellular infiltration, lymphoid aggregates, obliterative macrovascular lesionsHistologic analysis (tissue staining)Lining layer thickness, global cellular infiltration, lymphoid aggregates, obliterative macrovascular lesions were all more common in A-RLA compared with other arthritis cases*MMPs* matrix metalloproteinases, *PBMCs* peripheral blood mononuclear cells, *SF* synovial fluids, *FLS* fibroblast-like synoviocytes, *hECGF* human endothelial cell growth factor, *EM* erythema migrans, *DbpA* decorin binding protein A, *VlsE* variable major protein-like sequence expressed lipoprotein, *Arp* arthritis-related protein, *OspA* outer surface protein A, *OspC* outer surface protein C, *CRP* C-reactive protein, *GITR* glucocorticoid-induced TNFR-related protein, *A-RLA* antibiotic-refractory Lyme arthritis

Compared with healthy controls, A-RLA patients exhibited significantly higher levels of C-reactive protein (CRP) in their blood or synovial fluid/tissue \[[@CR36]\]. Compared with antibiotic-responsive LA patients, studies found a significantly higher level of immune mediators associated with T-helper 1 and T-helper 17 cell immune responses, such as CCL2, CCL3, CCL4, TNF-α, CXCL9, CXCL-10, IL-6, IL-8, IL-10, IL-1β, IL-17F, IL-23 and IFN-γ \[[@CR13], [@CR21], [@CR27], [@CR31]\]. Furthermore, A-RLA patients demonstrated significantly higher expression of the *B. burgdorferi* proteins p58 and outer surface protein (Osp) C compared with their antibiotic-responsive LA counterparts \[[@CR11]\]. One study investigated histologic findings in the synovial tissue of A-RLA patients compared with other arthritis patients and found differences in lining layer thickness, global cellular infiltration, lymphoid aggregates and obliterative macrovascular lesions, which were more common in A-RLA patients \[[@CR17]\].

When examining immune cell types, compared with healthy controls, A-RLA patients had higher levels of memory CD4^+^ T cells \[[@CR18]\] in peripheral blood, while the CD3^+^ T cells were significantly lower \[[@CR20]\]. Compared with antibiotic-responsive LA patients, A-RLA patients had lower levels of CD4^+^ T cells \[[@CR18]\] (although higher levels were observed in one study \[[@CR34]\]), CD56bright natural killer (NK) cells \[[@CR20]\] and Vα24^+^ NKT cells \[[@CR20]\] in synovial fluid. Higher numbers of IL-4^+^CD4^+^ Th2 cells, IL-17^+^CD4^+^ T cells and FoxP3^+^ Treg cells were all found in A-RLA patients compared with antibiotic-responsive subjects \[[@CR22]\]. One study, however, did not find a significant difference in OspA161-175-specific T-cell frequencies or proliferation responses between A-RLA and responsive patients \[[@CR23]\].

Five studies evaluated the genetic markers of A-RLA (Table [3](#Tab3){ref-type="table"}). Of those, two studies examined the microRNA (miRNA) expression and reported that miR-146a, miR-142, miR-17, miR-155, miR-223 and miR-20a were significantly elevated in post- vs. pre-antibiotic treated A-RLA \[[@CR12]\]. These miRNA species, in addition to let-7a, let-7c and miR-30fam, were also significantly higher in A-RLA patients compared with patients with osteoarthritis \[[@CR12], [@CR29]\]. Patients with A-RLA also exhibited higher levels of miR-146a, miR-155, miR-223 and miR-142 than the antibiotic-responsive LA patients \[[@CR29]\]. Another study reported the frequency of the 1805GG single-nucleotide polymorphism (SNP) in the Toll-like receptor-1 gene (*TLR*-*1*) to be significantly lower in A-RLA patients than in the antibiotic-responsive LA patients \[[@CR35]\]. Cells with this 1805GG SNP were shown to have an altered mRNA expression of the suppressor of cytokine signaling (SOCS)-3, suggesting that greater inflammatory responses in A-RLA patients with this polymorphism may be due to the loss of a cytokine regulatory pathway \[[@CR28]\]. Lastly, allele haplotype frequencies of human leukocyte antigen (HLA) were investigated in one study and found that HLA-DRB1-DQA1-DQB1 haplotype frequencies were similar between A-RLA patients and subjects with antibiotic-responsive LA \[[@CR26]\]. However, the frequency of DRB1 alleles differed markedly, and a significantly larger number of A-RLA patients showed binding to the outer surface protein A (OspA) than their antibiotic-responsive LA counterparts \[[@CR26]\]. Our systematic assessment of the literature allowed us to identify an array of biomarkers that are commonly upregulated in the A-RLA compared with subjects with antibiotic-responsive LA (Table [4](#Tab4){ref-type="table"}). These included a range of inflammatory markers (IL-6, IL-8, IL-10, IL-1β, IL-23, IL-17F, TNFα, IFNγ, CXCL9, CXCL10, CCL2, CCL3 and CCL4, CRP), factors related to innate and adaptive immune responses (e.g., CD4^+^ T cells, GITR receptors, OX40 receptors, IL-4^+^CD4^+^ Th2 cells, IL-17^+^CD4^+^ T-cells) and biomarkers such as annexin A2, hECGF.Table 3Summary of studies reporting genetic biomarkers in antibiotic-refractory LA in humansStudyBiomarker classBiomarker(s)AssaySummary of resultsLochhead et al. 2017 \[[@CR12]\]miRNAmiR-146a, miR142, miR17, miR-155, miR-223, miR20a, let-7a, let-7cPCRmiR-146a, miR142, miR17, miR-155, miR-223 and miR20a were higher in post- vs. pre-antibiotic treated A-RLA\
miR-146a, miR142, miR17, miR-155, miR-223, miR20a, let-7a and let-7c were higher in A-RLA compared with osteoarthritisLochhead et al. 2015 \[[@CR29]\]miRNA (extracellular)miR-146a, miR-155 (inflammatory signature), miR-30fam (vascularization signature), miR223, miR142qPCRmiR-146a, miR-155, miR-223 and miR-142 were higher in A-RLA compared with antibiotic-responsive LA\
miR-146a, miR-155, miR-30fam, miR223 and miR-142 were upregulated in A-RLA compared with osteoarthritis patientsStrle et al. 2015 \[[@CR28]\]mRNA expression*SOCS3* mRNA expression in cells with 1805GG polymorphism in *TLR1*QuantiGene and whole-genome RNASeqAltered *SOCS3* mRNA expression in A-RLA compared with antibiotic-responsive LA, i.e., greater inflammatory responsesStrle et al. 2011 \[[@CR35]\]SNPsFrequency of 1805GG polymorphism in *TLR1* genePCRFrequency of the 1805GG polymorphism was lower in A-RLA compared with antibiotic-responsive LASteere et al. 2006 \[[@CR26]\]HLA typing and binding to OspAHLA-DRB1-DQA1-DQB1/DRB1 allele frequencyHigh-resolution molecular HLA typingHLA-DRB1-DQA1-DQB1 haplotype frequencies were similar between A-RLA and responsive LA\
Larger number of A-RLA patients showed binding to OspA compared with antibiotic-responsive LA*SNPs* single-nucleotide polymorphisms, *TLR* Toll-like receptors, *OspA* outer surface protein A, *SOCS-3* suppressor of cytokine signaling-3, *HLA* human leukocyte antigen Table 4Summary of commonly upregulated biomarkers in antibiotic-refractory vs. -responsive LA in humansBiomarker classBiomarkerSpecimensInflammatory markersIL-6, IL-8, IL-10, IL-1β, IL-23, IL-17F, TNFα, IFNγ, CXCL9, CXCL10, CCL2, CCL3, CCL4, CRPSerum and synovial fluidsImmunity-related markersmiR-146a, miR-155, miR-223 and miR-142, CD4^+^ T-cells, GITR receptors, OX40 receptors, IL-4^+^ CD4^+^ Th2 cells, IL-17^+^CD4^+^ T-cells and FoxP3^+^Treg cellsPeripheral blood and synovial fluidsOther markersAnnexin A2, hECGFSerum and synovial fluids

Discussion {#Sec8}
==========

To date, there is a relatively limited evidence base of large, adequately powered studies to assess the predictive ability of biomarkers for A-RLA. Most studies presented here did not include more than 120 A-RLA cases. However, there is emerging information to suggest an array of both immunologic and genetic biomarkers that can be utilized in characterizing A-RLA. While most studies focused on immune response biomarkers, including cytokines, chemokines and immune cell typing, there were also a number of studies evaluating a range of genetic biomarkers, such as miRNAs, SNPs and haplotype frequencies that can be used to identify or predict a status of A-RLA in LB patients.

Of the genetic biomarkers that have been studied, there are several miRNAs that appear to be the highly promising. The miRNAs are small non-coding RNA molecules that function in post-transcriptional gene regulation \[[@CR37], [@CR38]\]. Altered miRNA expression has been implicated in the pathogenesis of several inflammatory and autoimmune diseases, including rheumatoid arthritis \[[@CR39], [@CR40]\]. In addition to inflammatory responses, miRNAs can also play a role in bone destruction and remodeling \[[@CR41]\]. Only two studies examined differential miRNA expression in A-RLA patients in which some of the miRNAs identified here are consistent with those characterized in rheumatoid arthritis, i.e., miR-146a, miR-155, miR-223 and let-7a \[[@CR39]\]. Other miRNAs, however, appear to be unique to A-RLA such as miR-142, miR-17, miR-20a, let-7c and miR-30fam \[[@CR12], [@CR29]\]. The miR-146 and miR-155 species are known to play a role in immune functioning as shown in mouse models where both were upregulated during *B. burgdorferi* infection \[[@CR42], [@CR43]\]. These studies demonstrated that miR-146a may act as a negative regulator of immune activation whereas miR-155 as a positive regulator \[[@CR42], [@CR43]\]. Important roles in cellular proliferation and regulation of inflammatory processes and responses were also suggested for miR-223 and miR-17 \[[@CR44]--[@CR46]\]. Higher levels of these miRNA species were reported in A-RLA patients \[[@CR12], [@CR29]\], indicating a status of dysregulated repair of the damaged tissue. With new insights into the roles of miRNAs in human diseases, it is likely that future research will reveal specific mechanisms through which these miRNAs contribute to A-RLA and how they may be used not only as predictive biomarkers of A-RLA patients but also as potential therapeutic targets.

There has been considerably more research on immune biomarkers as potential predictive factors of A-RLA. Of the most promising biomarkers examined, Th17-related cytokines appear to be of significant value. While several autoantigens have been identified that may be more prominent in A-RLA patients, such as MMP-10, annexin A2 \[[@CR15], [@CR33]\], apolipoprotein B-100 and ECGF \[[@CR14]--[@CR16], [@CR19], [@CR30], [@CR32], [@CR33]\], T-cell responses tend to occur later in LB manifestations and appear to be particularly associated with the manifestation of A-RLA \[[@CR47]\]. Th17 cells are a subgroup of T-helper cells that have been shown to play a key role in autoimmune diseases, such as rheumatoid arthritis \[[@CR48]\]. These cells are characterized by their ability to synthesize IL-17, a proinflammatory cytokine \[[@CR49]\] previously implicated in the development of LA \[[@CR8], [@CR50]\]. Furthermore, inhibition of IL-17 was shown to inhibit the development of LA in mouse models infected with *B. burgdorferi* \[[@CR51]\]. Findings from the present study indicate that IL-17F and IL-23 from Th17 cells are significantly elevated in A-RLA patients compared with antibiotic-responsive LA patients \[[@CR13], [@CR31]\]. The Th17 cells were also shown to play a role at the different LB stages in humans with a pronounced effect particularly at the early stages to help in combating the infection \[[@CR13]\]. A continued Th17 response appears, however, to evolve at the later infection stages to trigger autoimmunity and lead to inflammatory arthritis \[[@CR52]\]. Although their role in A-RLA in humans has yet to be fully elucidated, observations suggesting a role of the Th17 responses in the early as well as late stages of LB provide promise for their use in predicting disease complications, e.g., LA and/or A-RLA. In addition to Th17 responses, Th1 cells were also shown to play an important part in LA by providing a dominant immune response in the synovial fluid of LB patients \[[@CR53]\]. Other Th1 response or innate immune response biomarkers that can be employed to differentiate A-RLA from the responsive LA phenotype include IL-6, IL-8, IL-10, IL-1β, IL-17F, IL-23, IFN-γ, TNF-α, CCL2, CCL3, CCL4, CXCL9 and CXCL-10 \[[@CR13], [@CR21], [@CR27], [@CR31]\].

Despite targeting an emerging field in LB research, the present study has a number of limitations. As previously mentioned, most of the selected studies recruited a small number of A-RLA cases (i.e., *n *\< 120). These studies were likely, therefore, to be underpowered in detecting smaller changes in biomarker levels. In addition, a variety of controls were used between studies, which were typically healthy controls, other arthritis patients (i.e., rheumatoid arthritis, osteoarthritis) or antibiotic-responsive LA patients. This inconsistent selection on controls caused difficulty in generating a decisive evaluation for the predictive ability of the biomarkers across the studies and in the conversion of LA to A-RLA. Lastly, the reports included here were all case-control studies in which stored biospecimens were assessed retrospectively and may have not been standardized for all patients, e.g., in terms of timing for sample collection or if studies were multi-site in nature, leading to a lack of harmonized protocols across the selected studies. Furthermore, of the evaluated reports only one included examination of synovial tissue and synovial fluid \[[@CR25]\]. It has been well documented that in LB patients with persistent arthritis, the spirochetes are preferentially detected in synovial tissue rather than synovial fluid \[[@CR54]\]. This limitation may lead to an unsubstantiated conclusion that persistent spirochetal infection may be absent in A-RLA patients based on lack of synovial fluid testing.

As a few of the studies identified here were designed to examine the prediction of progression from LB to LA and subsequently to A-RLA, future studies need to be developed prospectively to adequately evaluate the predictive power of a selected set of factors from the biomarkers characterized here. Moreover, a comparison of the biomarkers proposed here---between patients with LA-related true joint swelling and those with joint pain---would be illuminating and can be proposed for future studies. Findings from these and other studies should also be validated against other similar study populations to evaluate the true predictive ability of the biomarkers of interest. Furthermore, future studies should investigate multiple biomarkers and combine both immune and genetic biomarkers to better compare---and strengthen---the prediction of A-RLA. It is likely that a combined biomarker approach in predicting resistance may yield the most clinical relevance as it examines multiple dysregulated pathways that play a concerted role in the etiology of A-RLA. Indeed, A-RLA is a joint disease that persists despite two-months of oral or one-month of intravenous antibiotics treatment \[[@CR6]\] and may simply require prolonged antibiotic therapy beyond these limited courses \[[@CR55]\]. Thus, the definition of "antibiotic refractory" appears to be an evolving concept, and the biomarker profiles described here could change with the different disease stages and therapy regimen.

Conclusion {#Sec9}
==========

In conclusion, the evidence base of biologic markers for A-RLA is limited to date. However, in the small set of studies conducted to date, a range of promising biomarkers have been identified. It appears that cytokines and chemokines related to the Th17 pathway together with a number of miRNAs species (miR-146a, miR-155 and let-7a) may be promising candidates in the prediction of A-RLA. Within well-powered and properly designed studies, a panel of multiple biomarkers may yield clinically relevant prediction of the possible antibiotic resistance at the time LA is first diagnosis.

Electronic supplementary material
=================================

 {#Sec10}

Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 224 kb)

**Enhanced digital features**

To view enhanced digital features for this article go to 10.6084/m9.figshare.7314683.

Funding {#FPar1}
=======

Public Health Agency of Canada funded the work presented in this article and the article processing charges (AB).

Authorship {#FPar2}
==========

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Authorship Contribution {#FPar3}
=======================

Alaa Badawi conceived the overall concept of the study and assisted in drafting the manuscript. Darren Brenner conducted the literature search and analysis and provided the first draft of the manuscript. Paul Arora advised on the analysis and assisted in interpretation of the results. All of the authors critically reviewed the manuscript, contributed substantive intellectual content and approved the final version submitted for publication.

Disclosures {#FPar4}
===========

Alaa Badawi, Darren Brenner and Paul Arora have nothing to disclose.

Compliance with Ethics Guidelines {#FPar5}
=================================

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability {#FPar6}
=================

All data generated or analyzed during this study are included in this published article and supplementary information files.

Open Access {#d29e2370}
===========

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
